image dons

I make a donation

APTITUDE

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor

Terminée

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

logo étude

objectif

Monocentric, biological, prospective, ex-vivo, trial aiming at comparing the effects of in vivo platelet transfusion on platelet activation in patients with bleeding caused by aorto-coronary bypass, depending on the type of inhibitor of the P2Y12 receptor (clopidogrel, prasugrel or ticagrelor) and the effects of ex-vivo transfusion with un-treated PRP on the normalisation of the platelet reactivity in SCA/PCI patients after a dosis of clopidogrel, prasugrel ou ticagrelor.

date de réalisation

2014

nombre de patients

45

nombre de centres participants

Monocentric (Pitié-Salpêtrière)

type de financement

Public (INSERM) and private (ACTION Group)

Référence

n°301111, CNIL n°1547216v0

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor : the APTITUDE study

Publication

  • Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor : the APTITUDE study
    Stephen A O'Connor, Julien Amour, Anne Mercadier, Réjane Martin, Mathieu Kerneis, Jérémie Abtan, Delphine Brugier, Johanne Silvain, Olivier Barthélémy, Pascal Leprince, Gilles Montalescot, Jean-Philippe Collet, ACTION Study Group
    Publicated in Circulation : Cardiovascular Interventions

Autres études

+

ANCHOR

En cours


Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients
+

ACORES-2

En cours


Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.
+

AFIJI

En cours


Impact of genetics on occuring of coronary diseases in young patients and the pharmacogenetic of clopidogrel and its impact on the prognosis of patients having had angioplasty